Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 16/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312338 | 0.95 | MLNR (0.47) | MLNRCYP3A4CYP2D6KCNH2CCR1 | |
| SCHEMBL2397561 | 0.91 | MLNR (0.44) | MLNRCYP3A4CHRM4CYP2D6KCNH2 | |
| SCHEMBL377495 | 0.88 | MLNR (0.54) | MLNRCYP3A4CYP2D6KCNH2CCR1 | |
| SCHEMBL1313169 | 0.87 | MLNR (0.52) | MLNRCYP3A4CHRM4CYP2D6KCNH2 | |
| SCHEMBL377498 | 0.86 | MLNR (0.64) | MLNRCYP3A4CYP2D6KCNH2 | |
| SCHEMBL378267 | 0.86 | MLNR (0.55) | MLNRCYP3A4CYP2D6KCNH2 | |
| SCHEMBL4210797 | 0.86 | MLNR (0.55) | MLNRCYP3A4CYP2D6KCNH2 | |
| SCHEMBL1313152 | 0.83 | MLNR (0.56) | MLNRCYP3A4CHRM4 | |
| SCHEMBL377798 | 0.83 | KDM4E (0.49) | MLNRCYP3A4CCR1FPR3GPR65 | |
| SCHEMBL2397562 | 0.82 | MLNR (0.39) | MLNRCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236953-B2 | Process for preparing piper azine derivatives | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-2029538-B1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | SEAL JONATHAN THOMAS | 2011-11-10 | — | — | US | disclosed |
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131453-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | MLNR 6/4885CYP3A4 1156/4885CHRM4 395/4885 |
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | MLNR 6/4885CYP3A4 1156/4885CHRM4 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.